小儿肺热咳喘颗粒联合布地奈德治疗小儿支气管肺炎痰热壅肺证52例临床观察  

Clinical observation on 52 cases of bronchopneumonia in children with accumulation of phlegm-heat in lung syndrome treated by Xiao’er Feire Kechuan Keli(小儿肺热咳喘颗粒) combined with budesonide

作　　者：俞丽君 YU Lijun(Department of Pediatrics,Shaoxing Central Hospital,Shaoxing,Zhejiang,312060,China)

机构地区：[1]绍兴市中心医院儿科,浙江绍兴312060

出　　处：《中医儿科杂志》2022年第3期54-57,共4页Journal of Pediatrics of Traditional Chinese Medicine

基　　金：浙江省中医药科技计划重点研究项目(2019ZZ010)。

摘　　要：目的 观察小儿肺热咳喘颗粒联合布地奈德治疗小儿支气管肺炎痰热壅肺证的临床疗效。方法 选取2019年1月至2020年12月绍兴市中心医院儿科收治的104例支气管肺炎痰热壅肺证患儿,采用随机数字表法分为治疗组和对照组,各52例。2组入院后均给予常规西医对症治疗,对照组在此治疗方法的基础上给予雾化吸入布地奈德混悬液,治疗组在对照组治疗方法的基础上给予小儿肺热咳喘颗粒,2组治疗7 d后,统计临床疗效、临床症状改善时间、血清炎症因子[C-反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)]水平变化和不良反应发生情况。结果 治疗组总有效率为94.23%(49/52),显著高于对照组的80.77%(42/52),2组比较,差异有统计学意义(P<0.05)。治疗组在退热时间及咳嗽、咳痰、肺部湿啰音消失时间方面均短于对照组,2组比较,差异有统计学意义(P<0.05)。治疗前,2组血清炎症因子CRP、IL-6、IL-8水平比较,差异无统计学意义(P>0.05),具有可比性;治疗后,2组上述血清炎症因子水平较同组治疗前显著降低(P<0.05),且治疗组降低更显著(P<0.05)。治疗组不良反应发生率为3.84%(2/52),对照组为7.69%(4/52),2组比较,差异无统计学意义(P>0.05)。结论 小儿肺热咳喘颗粒联合布地奈德治疗小儿支气管肺炎痰热壅肺证,临床疗效显著,可有效改善临床症状,减轻机体炎症反应,且无明显不良反应,值得临床推广应用。Objective To observe the clinical efficacy of Xiao’er Feire Kechuan Keli(小儿肺热咳喘颗粒)combined with budesonide in the treatment of bronchopneumonia in children with accumulation of phlegm-heat in lung syndrome.Methods From January 2019 to December 2020,104 cases of bronchopneumonia in children with accumulation of phlegm-heat in lung syndrome admitted into pediatrics department of Shaoxing Central Hospital were divided into treatment group and control group according to random number table method,with 52 cases in each group.Both groups were given routine symptomatic Western medicine treatment after admission.The control group was given nebulization inhalation of budesonide suspension on the basis of this therapeutic method,and the treatment group was given Xiao’er Feire Kechuan Keli on the basis of the therapeutic method of the control group.After 7 days of treatment,we kept statistics about clinical efficacy,alleviating time of clinical symptoms,changes in serum levels of inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6),interleukin-8(IL-8)]and incidence of adverse reactions.Results The total effective rate of the treatment group was 94.23%(49/52),which was significantly higher than 80.77%(42/52)of the control group,and the difference was statistically significant between the 2 groups(P<0.05).The treatment group was shorter than the control group in terms of time of abating fever,cough,expectoration and disappearance time of wet rales in the lungs,and the difference was statistically significant between the 2 groups(P<0.05).Before treatment,there was no statistically significant differences in the levels of serum inflammatory factors CRP,IL-6 and IL-8 between the 2 groups(P>0.05),indicating comparability.After treatment,the levels of above-mentioned serum inflammatory factors in the 2 groups significantly decreased than those in the same group before treatment(P<0.05),moreover,the decrease in treatment group was more significant(P<0.05).The incidence of adverse reactions was 3.84%(

关 键 词：支气管肺炎 小儿 小儿肺热咳喘颗粒 布地奈德 临床观察 

分 类 号：R725.6[医药卫生—儿科]